EVELO BIOSCIENCES INC (EVLO) Forecast, Price Target & Analyst Ratings
NASDAQ:EVLO • US2997342025
0.3165 USD
-0.05 (-14.46%)
At close: Dec 11, 2023
0.3159 USD
0 (-0.19%)
After Hours: 12/11/2023, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for EVELO BIOSCIENCES INC (EVLO).
Forecast Snapshot
Consensus Price Target
$10.20
+ 3,122.75% Upside
Next Earnings Forecast
Release DateMar 14, 2024
PeriodQ4 / 2023
EPS Estimate-$0.85
Revenue Estimate
ChartMill Buy Consensus
45.71%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$10.20
Upside
+ 3,122.75%
From current price of $0.32 to mean target of $10.20, Based on 7 analyst forecasts
Low
$10.10
Median
$10.20
High
$10.50
Price Target Revisions
1 Month
0.00%
3 Months
53.85%
Price Target Summary
7 analysts have analysed EVLO and the average price target is 10.2 USD. This implies a price increase of 3122.75% is expected in the next year compared to the current price of 0.3165.
The average price target has been revised upward by 53.85% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
45.71%
EVLO was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about EVLO.
In the previous month the buy percentage consensus was at a similar level.
EVLO was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-10-18 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2023-07-26 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-02-15 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-11-16 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2022-09-09 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-08-24 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-08-15 | Chardan Capital | Maintains | Buy |
| 2021-11-02 | JMP Securities | Maintains | Market Outperform |
| 2021-11-01 | Chardan Capital | Upgrade | Neutral -> Buy |
| 2021-06-23 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-06-23 | JMP Securities | Maintains | Market Outperform |
| 2021-05-03 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-04-12 | Jefferies | Upgrade | Hold -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 14, 2024
PeriodQ4 / 2023
EPS Estimate-$0.85
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q79.84%
Number of Analysts4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
-16.90%
Next Earnings Summary
EVLO is expected to report earnings on 3/14/2024. The consensus EPS estimate for the next earnings is -0.85 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A 335.19% | N/A 57.17% | ||||||||
| EBITDA YoY % growth | -12.53M | -26.7M -113.09% | -56.16M -110.34% | -84.6M -50.64% | -89.86M -6.22% | -113.17M -25.94% | -106.41M 5.97% | N/A 23.80% | N/A -6.42% | N/A -7.06% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -13.03M | -27.53M -111.28% | -58.1M -111.04% | -86.36M -48.64% | -91.89M -6.40% | -115.39M -25.57% | -108.47M 6.00% | N/A 34.27% | N/A 42.42% | N/A 5.71% | N/A -5.80% | N/A -3.61% | N/A 33.53% | N/A 100.00% | N/A | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.66 2.69% | -2.41 9.40% | -12.51 -419.09% | -29.00 -131.81% | N/A 85.07% | N/A 47.47% | N/A 8.74% | N/A 74.94% | N/A 152.94% | N/A 418.52% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.85 79.84% | -0.37 91.94% | -0.33 91.26% | -0.42 57.87% | -0.42 50.60% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -16.014M 24.07% | -9.69M 61.08% | -8.16M 54.54% | -15.147M -45.78% | -15.198M 5.10% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.47%
EPS Next 5 Year
14.98%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
7.12%
EBIT Next 5 Year
N/A
EVELO BIOSCIENCES INC / EVLO Forecast FAQ
What is the price target for EVLO stock?
7 analysts have analysed EVLO and the average price target is 10.2 USD. This implies a price increase of 3122.75% is expected in the next year compared to the current price of 0.3165.
When does EVELO BIOSCIENCES INC (EVLO) report earnings?
EVELO BIOSCIENCES INC (EVLO) will report earnings on 2024-03-14, after the market close.
Can you provide the consensus estimates for EVELO BIOSCIENCES INC next earnings?
The consensus EPS estimate for the next earnings of EVELO BIOSCIENCES INC (EVLO) is -0.85 USD and the consensus revenue estimate is 0 USD.
How many analysts have analysed EVELO BIOSCIENCES INC (EVLO)?
The number of analysts covering EVELO BIOSCIENCES INC (EVLO) is 7.